New journal devoted to hot button issue: childhood obesity

Share this article:
New journal devoted to hot button issue: childhood obesity
New journal devoted to hot button issue: childhood obesity

First Lady Michelle Obama's recent announcement of a campaign to end childhood obesity was not lost on medical publisher Mary Ann Liebert, Inc., which will roll out a new journal, Childhood Obesity, in June 2010.

The journal represents a re-branding of Liebert's Obesity and Weight Management, which will be folded into the new title. Vicki Cohn, executive VP and managing editor at Liebert, said the decision to focus the journal on childhood obesity was "not an advertising thing," but reflects "the enormous problem" of childhood obesity. "It's a hot subject," said Cohn.

The re-branded, peer-reviewed Childhood Obesity will offer original articles, perspectives from opinion leaders, safety and efficacy treatment regimens and case reports, among other features, to physicians, nurses and other healthcare professionals, according to a company statement.  

Cohn said Liebert has "maintained steady advertising sales" across its journal portfolio, which includes flagship Genetic Engineering and Biotechnology News, ASSAY and Drug Development Technologies, and AIDS Research and Human Retroviruses, among others covering biotechnology, medicine, surgery, nursing and integrative medicine. Liebert titles are primarily subscription-based, said Cohn, adding that the company's journals go out to 140 countries. For 2010, 15 Liebert titles will increase the number of issues published each year, according to the website.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.